10/06/2026
Before You Try Ozempic: What the Evidence Actually Shows About Long-Term Risks and Weight Regain
Something shifted in the past two years in how people talk about weight. Ozempic, Wegovy, Mounjaro, Rybelsus: names that a few years ago only endocrinologists used are now part of everyday conversation.
In the United States, 12.4% of adults reported currently using a GLP-1 medication (Glucagon-Like Peptide-1) specifically for weight loss by late 2025, up from 5.8% in early 2024 (Statista, 2025). In Europe, the numbers are much smaller, still under 1% in most countries, but the trajectory is steep and the media coverage even steeper.
If you are one of the millions of people weighing this option, or you know someone who is, this post is for you. I want to give you the same balanced, research-grounded picture I wish more mainstream sources would provide:
what these drugs actually do
what the evidence says about serious risks (including ones that appear or worsen months to years into treatment)
what happens to your weight when you stop, and
why the biological and psychological story behind obesity so often gets left out of the conversation.
Continue reading the post:
https://www.new-empowered-you.com/glp-1-weight-loss-risks/